hy 153724 sch 772984 mce (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
94
Structured Review
MedChemExpress
hy 153724 sch 772984 mce
Hy 153724 Sch 772984 Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+772984/BI-2865/pm41616775-288-21-23
Average 94 stars, based on 17 article reviews
Hy 153724 Sch 772984 Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+772984/BI-2865/pm41616775-288-21-23
Average 94 stars, based on 17 article reviews
hy 153724 sch 772984 mce - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Control:Article Title: ADAM10 and ADAM17 differently mediate induced pulmonary ACE release by either direct proteolysis or indirect upregulation protein synthesis. Article Snippet: ADAM10 and ADAM17 differently mediate induced pulmonary ACE release by either direct proteolysis or indirect upregulation protein synthesis Synthesized:Article Title: ADAM10 and ADAM17 differently mediate induced pulmonary ACE release by either direct proteolysis or indirect upregulation protein synthesis. Article Snippet: ADAM10 and ADAM17 differently mediate induced pulmonary ACE release by either direct proteolysis or indirect upregulation protein synthesis other:Article Title: PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia Article Snippet: The following compounds were added into culture medium at final concentrations indicated in the figure legends: Rapamycin (Sigma #553210) in DMSO, Inhibition:Article Title: UBE2T promotes β‐catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK‐dependent activation Article Snippet: Stable UBE2T overexpression monoclonal cell lines were generated by similar transfection conditions followed by puromycin selection (#P8833; Sigma‐Aldrich, St. Louis, MO, USA, 1 μg·mL −1 ). .. As for the inhibitor treatment, inhibition of: AKT was achieved with MK‐2206 (#HY‐10358, 5 μ m ), Wnt with IWP‐2 (#HY‐13912, 5 μ m ), Wnt/β‐catenin with IWR‐1 (#HY‐12238, 5 μ m ) and ERK with Solvent:Article Title: UBE2T promotes β‐catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK‐dependent activation Article Snippet: Stable UBE2T overexpression monoclonal cell lines were generated by similar transfection conditions followed by puromycin selection (#P8833; Sigma‐Aldrich, St. Louis, MO, USA, 1 μg·mL −1 ). .. As for the inhibitor treatment, inhibition of: AKT was achieved with MK‐2206 (#HY‐10358, 5 μ m ), Wnt with IWP‐2 (#HY‐13912, 5 μ m ), Wnt/β‐catenin with IWR‐1 (#HY‐12238, 5 μ m ) and ERK with Drug discovery:Article Title: Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas Article Snippet: Antibodies For Western blotting, the following antibodies were used: MYC (Abcam, catalog ab32072), β-actin (Santa Cruz Biotechnology Inc., catalog sc-47778HRP), RNAPII CTD phospho-Ser2 (Millipore, 04-1571-I), RNAPII CTD phospho-Ser5 (Millipore, 04-1572-I), RNAPII CTD phospho-Ser7 (Millipore, 04-1570-I), RNAPII CTD (Cell Signaling Technology, catalog 2629), p-p70S6K (Ser371) (Cell Signaling Technology, catalog 9208), p70S6K (Cell Signaling Technology, catalog 2708), p-4EBP1 (Thr37/46) (Cell Signaling Technology, catalog 2855), 4EBP1 (Cell Signaling Technology, catalog 9644), MCL-1 (Cell Signaling Technology, catalog 94296), BCL-2 (Cell Signaling Technology, catalog 2872), BCL-XL (Cell Signaling Technology, catalog 2762), cleaved PARP (Cell Signaling Technology, catalog 5625) and MDR1/ABCB1 (Cell Signaling Technology, catalog 12683). .. The following kinase and epigenetic inhibitors used in drug screening and cell-based drug screening assays: ABT-199 (Selleckchem, S8048), ABT263 (Selleckchem, S1001), A-1331852 (Selleckchem, S7801), ACP-196 (Selleckchem, S8116), Alisertib (Selleckchem, S1133), AZD7762 (Selleckchem, S1532), AZD8055 (Selleckchem, S1555), BEZ235 (Selleckchem, S1009), Bortezomib (Selleckchem, S1013), Carfizomib (Selleckchem, S2853), Dinaciclib (Selleckchem, S2768), Ibrutinib (Selleckchem, S2680), lenalidomide (Selleckchem, S1029), Lumpib (Selleckchem, S1069), MK-1775 (Selleckchem, S1525), Olaparib (Selleckchem, S1060), PIK-75 (Selleckchem, S1205), R406 (Selleckchem, S2194), Cell Culture:Article Title: Cryptochrome 2 stabilization alleviates psoriasis by inhibiting keratinocyte hyperproliferation and inflammation. Article Snippet: Psoriasis, a chronic inflammatory skin disorder, is characterized by aberrant keratinocyte proliferation and immune dysregulation.. Although cryptochrome 2 (CRY2), a circadian rhythm regulator, has been implicated in inflammatory conditions, its role in the psoriasis pathogenesis remains elusive.. Here, we report a marked downregulation of CRY2 expression in psoriasis, which was reversed upon biological therapy, suggesting its pivotal involvement in disease progression. |